Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain

References

• Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–1969. doi: 10.1182/blood.2020007338.
   PubMed Web of Science ®Google Scholar
• Marin-Barrera L, Muñoz-Martin AJ, Rios-Herranz E, et al. A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: quality of life in cancer (qca) study. Cancers (Basel). 2019;12(1):75. doi: 10.3390/cancers12010075.
   PubMed Web of Science ®Google Scholar
• Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. doi: 10.1371/journal.pmed.1001275.
   PubMed Web of Science ®Google Scholar
• Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematol Am Soc Hematol Educ Program. 2012;2012(1):626–630. doi: 10.1182/asheducation.V2012.1.626.3798655.
   PubMedGoogle Scholar
• Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949. doi: 10.1016/S1470-2045(09)70232-3.
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609. doi: 10.1056/NEJMoa1108898.
   PubMed Web of Science ®Google Scholar
• Rutjes AW, Porreca E, Candeloro M, et al. M. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2020;12(12):CD008500.
   PubMedGoogle Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi: 10.1200/JCO.19.01461.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. 2022 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. doi: 10.1016/S1470-2045(22)00160-7.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, AVERT Investigators, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719. doi: 10.1056/NEJMoa1814468.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. doi: 10.1056/NEJMoa1814630.
   PubMed Web of Science ®Google Scholar
• Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020;22(2):171–186. doi: 10.1007/s12094-019-02263-z.
   PubMed Web of Science ®Google Scholar
• Holmes CE, Ades S, Gilchrist S, et al. Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic. J Clin Oncol Oncol Pract. 2020;16(9):e868–e874. pdoi: 10.1200/JOP.19.00697.
   PubMedGoogle Scholar
• Du J, Wu B. New oral anticoagulants for thromboprophylaxis in patients with cancer receiving chemotherapy: an economic evaluation in a Chinese setting. Clin Drug Investig. 2020;40(7):653–663. doi: 10.1007/s40261-020-00926-2.
   PubMed Web of Science ®Google Scholar
• Li A, Carlson JJ, Kuderer NM, et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020;126(8):1736–1748. doi: 10.1002/cncr.32724.
   PubMed Web of Science ®Google Scholar
• Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014;6:179–187. doi: 10.2147/CPAA.S61131.
   PubMedGoogle Scholar
• Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, et al. Análisis coste-efectividad de apixaban frente a dabigatrán en la prevención de la tromboembolia venosa en pacientes intervenidos de artroplastia total de rodilla o de cadera. Rev Esp Cir Ortop Traumatol. 2012;56(6):459–470. doi: 10.1016/j.recot.2012.07.009.
   PubMedGoogle Scholar
• Kimpton M, Kumar S, Wells PS, et al. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. CMAJ. 2021;193(40):E1551–E1560. doi: 10.1503/cmaj.210523.
   PubMed Web of Science ®Google Scholar
• Ryan E, Salinaro J, Havrilesky LJ, et al. Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: a cost-effectiveness analysis. J Clin Oncol. 2020;38(15_suppl):7074–7074. Available at. doi: 10.1200/JCO.2020.38.15_suppl.7074.
   Web of Science ®Google Scholar
• Glickman A, Brennecke A, Tayebnejad A, et al. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery. Gynecol Oncol. 2020;159(2):476–482. doi: 10.1016/j.ygyno.2020.07.096.
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford (UK): Oxford University Press; 2006.
   Google Scholar
• Agnelli G. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. N Engl J Med. 2019;380(8):781–783. doi: 10.1056/NEJMe1816060.
   PubMed Web of Science ®Google Scholar
• Martinez C, Wallenhorst C, Teal S, et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England. Pulm Circ. 2018;8(3):2045894018791358–2045894018791310. doi: 10.1177/2045894018791358.
   Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264. doi: 10.1056/NEJMoa032274.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82(4):423–428.
   PubMed Web of Science ®Google Scholar
• Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994.
   Google Scholar
• Pudar S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Method. 2005;5:13.
   PubMedGoogle Scholar
• Tarifas para facturación de servicios sanitarios y docentes del servicio vasco de salud para el año. 2020. Diciembre 2019. Available at https://www.osakidetza.euskadi.eus/contenidos/informacion/osk_servic_para_empresas/es_def/adjuntos/LIBRO-DE-TARIFAS_2020_osakidetza.pdf. (accessed 17 September 2020).
   Google Scholar
• Lloyd AJ, Dewilde S, Noble S, et al. What impact does venous thromboembolism and bleeding have on cancer patients’ quality of life? Value Health. 2018;21(4):449–455. doi: 10.1016/j.jval.2017.09.015.
   PubMed Web of Science ®Google Scholar
• Hu B, Fu AZ. Predicting utility for joint health states: a general framework and a new nonparametric estimator. Med Decis Making. 2010;30(5):E29–E39. doi: 10.1177/0272989X10374508.
   PubMed Web of Science ®Google Scholar
• Vreman RA, Geenen JW, Knies S, et al. The application and implications of novel deterministic sensitivity analysis methods. Pharmacoeconomics. 2021;39(1):1–17. doi: 10.1007/s40273-020-00979-3.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? [What is an efficient health intervention in Spain in 2020?]. Gac Sanit. 2020;34(2):189–193. doi: 10.1016/j.gaceta.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488. doi: 10.1182/blood-2002-01-0108.
   PubMed Web of Science ®Google Scholar
• Kaplan RM. The minimally clinically important difference in generic utility-based measures. COPD. 2005;2(1):91–97. doi: 10.1081/copd-200052090.
   PubMedGoogle Scholar
• Wee HL, Machin D, Loke WC, et al. Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health. 2007;10(4):256–265. doi: 10.1111/j.1524-4733.2007.00174.x.
   PubMed Web of Science ®Google Scholar
• Muñoz A, Ay C, Grilz E, et al. A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts. J Clin Oncol. 2023;41(16):2911–2925. doi: 10.1200/JCO.22.00255.
   PubMedGoogle Scholar
• Li A, La J, May SB, et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems. J Clin Oncol. 2023;41(16):2926–2938. doi: 10.1200/JCO.22.01542.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi: 10.1056/NEJMoa1915103.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi: 10.1200/JCO.2018.78.8034.
   PubMed Web of Science ®Google Scholar
• Isla D, De Castro J, Juan O, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res. 2017;9:31–38. doi: 10.2147/CEOR.S121093.
   PubMed Web of Science ®Google Scholar
• Anguita P, González C, Cañete M, et al. Coste de los efectos adversos asociados a enzalutamida o apalutamida en el tratamiento del cáncer de próstata resistente a la castración no metastásico en España. Rev Esp Econ Salud. 2019;14(4):794–805.
   Google Scholar